Drug intelligence / Profile preview

OWP-108

Development stage: Preclinical
Lead developer: OWP Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

OWP-108 is a preclinical-stage small molecule candidate being developed by OWP Pharmaceuticals for the treatment of psychiatric disorders. As of 2024, the specific chemical identity, mechanism of action, and biological target of OWP-108 remain undisclosed by the sponsor. The drug is designed for oral administration. OWP Pharmaceuticals focuses on neuroscience and typically utilizes the 505(b)(2) regulatory pathway for reformulated products or develops new chemical entities to address unmet needs in epilepsy and psychiatry.

Beyond the preview

Go deeper on OWP-108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OWP-108.

Explore the full profile